NCT06769984View on ClinicalTrials.gov

A Study of SCTT11 in Healthy Participants and Participants with Thyroid Eye Disease.

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

February 19, 2025

Primary Completion Date

June 24, 2026

Study Completion Date

September 19, 2028

Conditions

TED

Interventions

DRUG

SCTT11

SCTT11 dose 1, dose 2, dose 3, dose 4

DRUG

Placebo

Placebo dose 1, dose 2, dose 3, dose 4

All Listed Sponsors

lead

Sinocelltech Ltd.

INDUSTRY